Between 30% to 50% of most cancers circumstances are preventable, in keeping with the World Health Organization. Precluding the development of most cancers can save patients and payers money and result in a greater high quality of life.
Feyi Ayodele, founder and CEO at CancerIQ, sat down with MobiHealthNews to debate CancerIQ’s choices and the way healthcare organizations use its expertise to detect and thwart the acceleration of most cancers in sufferers vulnerable to the illness.
MobiHealthNews: Are you able to inform our viewers about CancerIQ?
Feyi Ayodele: CancerIQ is an organization on a mission to essentially broaden entry to the most recent improvements in most cancers prevention, early detection and remedy.
MHN: And the way does it do this?
Ayodele: We do this by ensuring we’re actually totally integrating genomic drugs into routine care. The extra we study concerning the relationship between most cancers and our genes and different components because the science evolves, we must always be capable of act on that data. Basically, what we do is we make it in order that your on a regular basis supplier can use that data and design a customized care plan.
MHN: What position does digital well being play in your providing?
Ayodele: So, how we have carried out it really goes again to sort of a founding story. So, I began this firm after working with my mom, who’s a world-renowned breast medical oncologist and most cancers geneticist on the College of Chicago, which is de facto one of many founding members of this preventive oncology program.
And what I acknowledged as she was making an attempt to scale this program past the College of Chicago into their associates is that a number of the associates mentioned they did not have the time, they did not have the data, and, , they finally did not have the assets to do issues the best way my mom was doing issues on the College of Chicago.
So, I sort of work with the specialists within the subject … to automate and digitize a number of the method of preventive oncology, beginning up entrance with automating the household historical past information assortment, a number of stuff you gather from sufferers in order that we’re saving suppliers time in gathering data to resolve the data difficulty.
We’re actually a content material engine that has all the newest, most cutting-edge scientific tips and serves these up for suppliers and sufferers. And in addition automating the continuing administration course of. My mom had a full group of navigators that sort of known as sufferers that have been at elevated danger, ordered their MRIs, adopted up with them as a result of they must do one thing that is much more time intensive than different populations, and we have automated that course of as properly.
So, basically, we have taken a scientific service and we digitized it, which is, I believe, the definition of digital well being.
MHN: How are healthcare techniques utilizing CancerIQ’s choices?
Ayodele: One of many first issues that they are utilizing CancerIQ to do is to essentially broaden the genetic service or launch a genetic service.
So, they’re placing our software program within the palms of the suppliers who could also be skilled to do that already, and thru that course of automation they have been capable of double their service capability or broaden it to extra sufferers. In order that’s a technique that well being techniques are utilizing it.
The opposite means that well being techniques are utilizing it’s they’re really totally counting on CancerIQ to launch that new service inside their group. So, we’re increasing the genetics workforce by really giving our software program to suppliers who aren’t skilled in genetics, and thru automation, and once more, that the content material that we have by way of it, we are able to flip your on a regular basis supplier into that MacArthur Genius award-winning medical oncologist like my mother.
MHN: How does CancerIQ enhance entry to genetic testing?
Ayodele: The best way CancerIQ is increasing entry is we’re basically offering a extra high-resolution view of a affected person inhabitants. So, suppliers know these ones that want genetic testing want one thing above and past the usual of care as a result of in the event that they accurately determine these sufferers, they’re actually low-cost methods for sufferers to entry these companies.
MHN: What’s in retailer for 2024?
Ayodele: So, in 2024, we’re capitalizing on a few actually sturdy headwinds for CancerIQ.
There’s been some latest information about how ASCO [American Society of Clinical Oncology] has modified its tips and made it so that everyone with breast most cancers ought to get genetic testing. What does that imply? That signifies that extra sufferers are going to get entry, and we’ll discover extra mutation carriers this 12 months than we ever have.
The second factor that is actually thrilling for CancerIQ is that there is growing consciousness of those later-stage youthful sufferers who’re getting most cancers.
So, for 2024, a number of what CancerIQ is concentrated on isn’t just getting folks entry to testing or figuring out them in danger, however really actually deeply investing in the best way that we handle these sufferers at elevated danger, as a result of we’ll have a inhabitants of mutation carriers and high-risk sufferers that’s most likely the most important inhabitants this well being system has ever needed to handle.
And I believe by way of investments in our software program, we’re going to have the ability to amplify the efforts of each clinician and ensure these sufferers keep on monitor and keep forward of most cancers.
Basically, what we’re doing is giving everybody a hyper-personalized most cancers prevention plan. I might say that is sort of the layperson’s view of this. Genetic testing is simply one of many issues that will get carried out within the CancerIQ workflow, however we’re not a genetic testing lab. The truth is, we most likely course of extra assessments than a few of the genetic testing labs which can be on the market with out really proudly owning a lab in any respect.
We’re actually within the enterprise of decoding this data, ensuring it is attending to sufferers and is actually of their palms, so that every one affected person populations can actually act on the knowledge, versus simply getting examined by itself.
